Hjem › Akut bifænotypisk leukæmi › Michigan
Akut bifænotypisk leukæmi kliniske forsøg i Michigan
4 studier for Akut bifænotypisk leukæmi søger deltagere på steder i Michigan.
Byer i Michigan
Officiel studietekst (engelsk)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- C S Mott Children's Hospital, Ann Arbor
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Bronson Methodist Hospital, Kalamazoo
RekruttererFase 2
365 Days · Alle køn · Opdateret 25. sep. 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- C S Mott Children's Hospital, Ann Arbor
- Children's Hospital of Michigan, Detroit
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- og 2 flere
RekruttererFase 3
365 Days – 25 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- C S Mott Children's Hospital, Ann Arbor
- Children's Hospital of Michigan, Detroit
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- og 2 flere
RekruttererFase 1/2
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- C.S. Mott Children's Hospital, Ann Arbor
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.